Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG

156 Annual Financial Statement Konzern-Jahresabschluss
During the business year KEUR 691 deferred tax expenditures were recognized as net equity without
effect on profit and loss since the reason for the deferred taxes is a currency conversion of group internal
clearing account balances with net investment character which have also been recognized as net equity.
Pursuant to IAS 12.81, the actual tax expense must be compared to the fictitious tax expense that would
have resulted, if the applicable tax rates had been applied to the reported annual results before taxes
(theoretical tax burden).
In the following reconciliation calculation the expected tax expense is lead over to the actual recognized
tax expenses.
2009 / 2010
K Euro
2008 / 2009
K Euro
Income before income taxes and minority interest (159) (2,798)
Income tax rate (including Business trade tax) 30.53% 30.53%
Expected tax expense 49 854
Deferred taxes on losses fiscal year 0 830
Effect by deferred taxes on losses carried forward ( incl. tax rate
change in 2007/2008)
0 190
Effect by deferred taxes on temporary differences 0 (408)
Deviation towards foreign tax rates (47) (35)
Value adjustments of deferred taxes on losses carried forward 0 0
Total tax expense 2 1,431
5.7 Minority interest
Minority Interest % 2009 / 2010
Euro
AndaOptec 34.8 (4,284)
biolitec Italy 49 (36,302)
biolitec USA 10 (87,273)
CeramOptec USA 10 1,934
GlycoSense 25 (947)
biolitec Private India 0.2 2,604
biolitec Argentina 5 (123)
biolitec Russia 4 33,951
(90,440)
2008 / 2009
Euro
(1,797)
9,141
0
3,655
(494 )
(65)
(593)
0
9,847
In each case, the minority interest for the fiscal year was calculated as the amount after income taxes.
Losses have been assigned to the minorities according to their share in capital and further losses remain
with biolitec AG.